Journal of Bioequivalence & Bioavailability

Rahul Deshmukh

Rahul Deshmukh
College of Pharmacy
Rosalind Franklin University , USA

Biography

Dr. Rahul Deshmukh, Assistant Professor of Pharmaceutical Sciences, joined the College in 2011. Dr Deshmukh received his B.S. in Pharmacy from the University of Mumbai in 1996, followed by a Master in Pharmacy in 1998 from the same university. He went on to obtain a Ph.D. in Pharmaceutical Sciences in 2003, from University of Maryland. Following postdoctoral studies in the School of Pharmacy at West Virginia University, he pursued drug discovery and development research in the pharmaceutical industry for 6 years. In industry, his research was focused on understanding and improving the Absorption, Distribution, Metabolism and Excretion (ADME) properties of preclinical drug candidates. In his current role, Dr Deshmukh is responsible for developing the Pharmaceutics Course Curriculum for the Pharm D program. In addition, he is also responsible for developing the Basic Pharmacokinetics and Pharmacodynamics course curriculum.

Research Interest

In addition to efficacy, factors critical for development of a successful drug candidate include good drug metabolism and pharmacokinetic (DMPK) properties along with minimal toxicity. Generally, inferior DMPK properties result in poor absorption, high clearance and have been attributed to the failure of oral drugs during the clinical development. In addition, potential of drug interactions or their inadequate understanding can complicate successful drug development. The prediction of human pharmacokinetics and metabolism of drugs is critical to advance the right compounds into clinical settings. Though, use of in vitro data to extrapolate in vivo has aided the effort allowing for prediction of pharmacokinetic parameters, with our current understanding, the translation to a clinical outcome is far from accurate. I hope to build a research program that is aimed at improving our understanding and prediction of DMPK properties of drugs using in silico and in vitro tools. Specifically my research will be focused on understanding mechanisms of CYP mediated drug-drug interactions (DDIs); pharmacokinetic modeling of CYP-dependent DDIs; in vitro-in vivo correlations of drug clearance and drug interaction and the effect of CYP polymorphisms on drug clearance.